GreenStar’s Science Advisory Board will provide guidance and external review of our research and development activities

 GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) (“GreenStar” or the “Company”) is pleased to announce the formation and launch of its science advisory board (the “Science Advisory Board”) and the appointment of its first distinguished board member, Dr. Mark Geyer, Professor Emeritus at University of California San Diego, who is a recognized pioneer in the psychedelics industry.


The Science Advisory Board will serve as a strategic resource for the Company to provide independent, expert, multi-disciplinary and strategic advice on initiatives. This will include exploration and research of psychedelics and medical device development. The board will provide guidance on research and clinical development strategy, with a view to helping the Company identify new opportunities for differentiation and innovation in the area of psychedelic medicine, and to identify and address future trends.

Dr. Mark A. Geyer, Ph.D.

Dr. Mark A. Geyer Ph.D. is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (“UCSD“). He directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. Since receiving his doctorate in Psychology in 1972, he has focused on basic research addressing the behavioral and neurobiological effects of psychedelics and other psychoactive drugs. For over four decades, his group has had continuous funding from the National Institute on Drug Abuse to study the behavioral effects of hallucinogens.

Dr. Geyer is internationally known for his research on the psychophysiology, neurobiology, and pharmacotherapy of schizophrenia and bipolar disorder. He has published over 470 peer-reviewed papers, including many addressing the mechanisms subserving the effects of psychostimulants, hallucinogens, and entactogens. He is the lead Series Editor for Current Topics in Behavioral Neurosciences, which has completed 43+ volumes. He was involved intensively in the NIMH-funded MATRICS, TURNS, and CNTRICS Programs. He has served as a receiving Editor of Neuropsychopharmacology, Neuropharmacology, Psychopharmacology, and Schizophrenia Bulletin, and as Scientific Advisor to European Union’s Innovative Medicine Initiative. He is a Fellow of the American Association for the Advancement of Science (“AAAS“), American College of Neuropsychopharmacology (“ACNP“), and American Psychological Society, Past-President of the International Society for Serotonin Research and the International Behavioral Neuroscience Society, member of Scientific Council of the Brain and Behavior Research Foundation, 2011 awardee of Bleuler Prize for Research in the Schizophrenias, and the 2014 Julius Axelrod Mentorship Awardee from ACNP. Dr. Geyer’s broad experience as a researcher, grant reviewer, journal editor, and teacher lends invaluable scientific and professional expertise to several organizations, as he provides the leadership to develop a strong program in the behavioral psychopharmacology and clinical applications of psychedelic agents.

Dr. Geyer is also on the scientific advisory board of the Beckley Foundation and in 1993 co-founded the Heffter Research Institute, which are two of the most prominent psychedelic organizations worldwide. The Beckley Foundation has been at the forefront of global drug policy reform and scientific research into psychoactive substances and the Heffter Research Institute has pioneered and supported much of the scientific research that has prompted the exploration of psychedelics as potential therapeutics in humans. He has recently co-founded the Psychedelics and Health Research Initiative at UCSD, which is exploring the efficacy of psychedelics in the treatment of pain disorders.

Maghsoud Dariani, Chief Science Officer of GreenStar said, “We are both honored and humbled to have someone of Mark’s caliber and pedigree join our Science Advisory Board. As we prepare for the start of our pre-clinical studies with the University of Miami, Dr. Geyer’s experience in research with psychedelics will be a significant asset for us.”

About GreenStar

GreenStar is a growth-oriented technology & services company that provides real estate, financial, management, IP & branding support to businesses. The Company operates a growing portfolio of tenant partner companies focused on developing transformational medicines and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies by leveraging its capital markets, branding and operational expertise.

For further information please contact:

GreenStar Biosciences Corp.
Thomas Baird, CEO
info@greenstarbiosciences.com
Tel: (604) 834-9499

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including statements regarding the future plans and objectives of the Company, the Company’s expectations surrounding its development of treatments for mTBI and PTSD and development of intellectual property and effective delivery methods and devices for such treatments, the Company’s expansion initiatives, research and development using psychedelic medicine and pursuit of M&A activity are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; and that the current Board and management may not be able to attain the Company’s corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/65355

News Provided by Newsfile via QuoteMedia

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less